{
    "clinical_study": {
        "@rank": "122500", 
        "arm_group": [
            {
                "arm_group_label": "Cisatracurium", 
                "arm_group_type": "Experimental", 
                "description": "Induction and maintaining of anaesthesia with Propofol. Analgesia either with Fentanyl or Fentanyl+Remifentanyl.\nCisatracurium (Nimbex):\ninitial dose: 0.2 mg/kg\nmaintaining dose: 0.1 mg/kg (repeated anytime TOF-count reaches 2 twitches)\nAt the end of the surgical operation, patients will be administered Neostigmine 0.04 mg/kg and Atropine 0.02 mg/kg.\nPatients will be extubated with a TOF-Ratio of at least 0.90."
            }, 
            {
                "arm_group_label": "Rocuronium", 
                "arm_group_type": "Experimental", 
                "description": "Induction and maintaining of anaesthesia with Propofol. Analgesia either with Fentanyl or Fentanyl+Remifentanyl\nRocuronium (Esmeron):\ninitial dose: 0.6 mg/kg\nmaintaining dose: 0.15 mg/kg (repeated anytime TOF-count reaches 2 twitches)\nAt the end of the surgical operation, patients will be administered Neostigmine 0.04 mg/kg and Atropine 0.02 mg/kg.\nPatients will be extubated with a TOF-Ratio of at least 0.90."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the incidence of post-operative residual\n      curarization in our patients and to determine if Cisatracurium and Rocuronium behave\n      differently from each other in terms of residual curarization."
        }, 
        "brief_title": "Comparison Between Cisatracurium and Rocuronium in Terms of Recovery of the Muscular Strength in the Postoperative Phase After Surgery and General Anaesthesia", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Postoperative Residual Curarization", 
            "Residual Neuromuscular Block"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  general anaesthesia with need to use of neuromuscular-blocking agents\n\n          -  awakening and extubation of the patient in the operating room and permanence in the\n             PACU for at least 60 minutes\n\n          -  age 18-80\n\n          -  surgical operations lasting at least 1 hour\n\n          -  ASA class I-III\n\n          -  possibility to apply TOF-monitoring with thumb-acceleromyography\n\n          -  women of childbearing age not using contraceptives\n\n          -  women of childbearing age using contraceptives\n\n        Exclusion Criteria:\n\n          -  subjects unable to give a valid consent\n\n          -  patients in emergency situations\n\n          -  patients not awakened and not extubated in the operating room\n\n          -  age above 80 years or under 18 years\n\n          -  surgical operations lasting less than an hour\n\n          -  ASA class IV\n\n          -  impossibility to apply and/or perform TOF-monitoring\n\n          -  neuromuscular diseases\n\n          -  intake of therapies interfering with the neuromuscular function\n\n          -  patients having contraindications for either studied drug\n\n          -  pregnant women\n\n          -  women who are breast-feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01651572", 
            "org_study_id": "2633Pbis", 
            "secondary_id": [
                "2012-002398-68", 
                "CURARI_2012"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Cisatracurium", 
                "description": "Cisatracurium (Nimbex):\ninitial dose: 0.2 mg/kg\nmaintaining dose: 0.1 mg/kg (repeated anytime TOF-count reaches 2 twitches)", 
                "intervention_name": "Cisatracurium", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Rocuronium", 
                "description": "Rocuronium (Esmeron):\ninitial dose: 0.6 mg/kg\nmaintaining dose: 0.15 mg/kg (repeated anytime TOF-count reaches 2 twitches)", 
                "intervention_name": "Rocuronium", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anesthetics", 
                "Rocuronium", 
                "Atracurium", 
                "Cisatracurium"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Postoperative residual curarization", 
            "Residual neuromuscular block", 
            "Complications", 
            "Postoperative", 
            "Neuromuscular function", 
            "Neuromuscular block"
        ], 
        "lastchanged_date": "March 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Padova", 
                    "country": "Italy", 
                    "zip": "35128"
                }, 
                "name": "Azienda Ospedaliera di Padova"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Assessment of Post-operative Residual Curarization (PORC) Incidence in Patients Undergoing Surgery With General Anaesthesia; Comparison Between Cisatracurium and Rocuronium. A Randomised, Single-blind Phase 4 Study.", 
        "overall_official": [
            {
                "affiliation": "Universit\u00e0 degli Studi di Padova - Azienda Ospedaliera di Padova", 
                "last_name": "Carlo Ori, Prof. M.D.", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Azienda Ospedaliera di Padova", 
                "last_name": "Paolo Feltracco, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Italy: Ethics Committee", 
                "Italy: National Monitoring Centre for Clinical Trials - Ministry of Health", 
                "Italy: The Italian Medicines Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To determine the incidence of post-operative residual curarization in our operating rooms, comparing two different neuromuscular-blocking agents: Cisatracurium and Rocuronium.\nThe primary endpoint is quantified with TOF-Ratio, determined with the device TOF-Watch SX (Organon, Netherlands). A TOF-Ratio<0.90 defines PORC.\nThree clinical parameters (head-tilt for 5 seconds, ability to swallow, presence of diplopia) are also evaluated.\nTOF-Ratios, as long as the above-mentioned clinical parameters are determined and evaluated at 15, 30 and 60 minutes after extubation of the patient.", 
            "measure": "Incidence of PORC", 
            "safety_issue": "Yes", 
            "time_frame": "Participants will be followed for the duration of their stay in the post-anaesthesia care unit (PACU), an expected average of 60 minutes."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01651572"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Azienda Ospedaliera di Padova", 
            "investigator_full_name": "Dr. Paolo Feltracco", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Incidence of PORC - comparison between Cisatracurium and Rocuronium", 
            "safety_issue": "Yes", 
            "time_frame": "Participants will be followed for the duration of their stay in the post-anaesthesia care unit (PACU), an expected average of 60 minutes."
        }, 
        "source": "Azienda Ospedaliera di Padova", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Azienda Ospedaliera di Padova", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}